84 related articles for article (PubMed ID: 23257916)
1. Simultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms.
Hauck G; Jonigk D; Kreipe H; Hussein K
Acta Haematol; 2013; 129(3):187-96. PubMed ID: 23257916
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
[TBL] [Abstract][Full Text] [Related]
3. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
D'Arena G; Gemei M; Luciano L; D'Auria F; Deaglio S; Statuto T; Bianchino G; Grieco V; Mansueto G; Guariglia R; Pietrantuono G; Martorelli MC; Villani O; Del Vecchio L; Musto P
J Clin Oncol; 2012 Nov; 30(32):e327-30. PubMed ID: 23008321
[No Abstract] [Full Text] [Related]
5. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
Fend F; Horn T; Koch I; Vela T; Orazi A
Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia developing in a patient with chronic myeloid leukemia: evidence of distinct lineage-associated genomic events.
Gargallo P; Cacchione R; Chena C; Dupont J; Garay G; Riveros D; Larripa I; Slavutsky I
Cancer Genet Cytogenet; 2005 Aug; 161(1):74-7. PubMed ID: 16080961
[TBL] [Abstract][Full Text] [Related]
7. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
8. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
10. Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia.
Crescenzi B; Sacchi S; Marasca R; Temperani P; La Starza R; Matteucci C; Bonacorsi G; Romoli S; Martelli MF; Mecucci C; Emilia G
Leukemia; 2002 May; 16(5):955-6. PubMed ID: 11986962
[No Abstract] [Full Text] [Related]
11. [Concurrent lymphoid and Philadelphia chromosome-negative myeloproliferative neoplasms].
Torregrosa JM; Soler G; Cancio S; Ferrer-Marin F
Med Clin (Barc); 2015 Oct; 145(7):318-9. PubMed ID: 25618739
[No Abstract] [Full Text] [Related]
12. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
13. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
14. The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Navarro-Vázquez M; González-Carrillo ML
Rev Invest Clin; 2006; 58(5):458-61. PubMed ID: 17408106
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
[No Abstract] [Full Text] [Related]
16. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Gattenlohner S; Völker HU; Etschmann B; Einsele H; Müller-Hermelink HK
Am J Hematol; 2009 May; 84(5):306-7. PubMed ID: 18951468
[No Abstract] [Full Text] [Related]
17. Simultaneous occurrence of chronic lymphocytic and chronic myeloid leukemia.
Katović SK; Vasilj A; Maricević I; Carzavec D; Jurić SC
Coll Antropol; 2010 Jun; 34(2):653-5. PubMed ID: 20698147
[TBL] [Abstract][Full Text] [Related]
18. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
19. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
Kronenwett R; Gräf T; Neumann F; Pechtel S; Steidl U; Diaz-Blanco E; Haas R
Leuk Res; 2006 Oct; 30(10):1323-4. PubMed ID: 16442619
[TBL] [Abstract][Full Text] [Related]
20. JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression.
Pahore ZA; Shamsi TS; Taj M; Farzana T; Ansari SH; Nadeem M; Ahmad M; Naz A
J Coll Physicians Surg Pak; 2011 Aug; 21(8):472-5. PubMed ID: 21798133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
